目的：探究分化型甲状腺癌患者术后行131I治疗的效果。方法根据TNM分期及MACIS评分标准，选择68例中高危分化型甲状腺癌患者（DTC），按照治疗方法分为对照组和治疗组，各34例。对照组患者术后不进行131 I治疗，治疗组患者术后进行131 I治疗。2年随访观察患者血清甲状腺球蛋白及甲状腺彩超。结果通过对68例中高危DTC患者2年的随访，发现对照组2年内TG值处于3～12ng/mL之间，且随术后时间推移，TG值由3.51 ng/mL不断升高至11.22ng/mL；而治疗组TG值明显低于对照组（P<0.05），2年内均保持在0.1ng/mL以内。同时对照组出现2例患者复发及1例患者出现转移灶，而治疗组2年内均无患者出现复发或转移灶，低于对照组5.88%的复发率及2.94%的远处转移率，但差异无统计学意义。结论分化型甲状腺癌患者术后采取131 I治疗是十分必要的，可以在一定程度内降低分化型甲状腺癌的复发率及远处转移率。%ObjectiveThe therapeutic effect of131I for postoperative patients with differentiated thyroid carcinoma was investigated. Methods According TNM staging and MACIS score,the high-risk patients with differentiated thyroid carcinoma (DTC) were selected in our hospital during 2006-2012 years, then were divided into two groups on the basis of different therapeutic methods. The control group hadn’t accepted131I therapy, and the therapy group had accepted131I therapy in postoperative. Patient’s serum thyroglobulin and thyroid ultrasonography were observed in the following two years.ResultsThrough investigating the 68 cases of high-risk patients with DTC, the value of TG was between 3-12 ng/mLin the control group in two years, and with postoperative time, TG values rising from the 3.51 ng/mLto 11.22 ng/mL; while the value of TG of the therapy group was significantly lower than control group(P<0.05), and maintained at less than 0.1 ng/mL. Furthermore, the control group had two cases of relapse and metastases in one patient; while there’s no one patient had recurrence or metastasis in the treatment group in the two years, it’s lower than the contronl group, in which the recurrence rate was 5.88% and distant metastasis rate was 2.94%.Conclusion Accepting131I therapy for differentiated thyroid cancer patients in postoperative is very essential, and it can reduce the recurrence rate and distant metastasis rate of differentiated thyroid cancer in a certain extent.
展开▼
